Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DDHD domain-containing protein 2 (DDHD2) is a phospholipase enzyme and triacylglycerol hydrolase that regulates lipid homeostasis in the central nervous system by catalyzing the hydrolysis of diacylglycerol and triacylglycerol and also acting as a phospholipase, preferably hydrolyzing phosphatidic acids. It contains functionally significant SAM, WWE, and DDHD domains, and participates in intracellular membrane trafficking, including mediating pathways between the endoplasmic reticulum and the Golgi apparatus. Mutations in DDHD2 disrupt lipid metabolism and trafficking and are associated with autosomal recessive spastic paraplegia type 54, a progressive neurodegenerative disease, as well as generalized epilepsy. The enzyme is widely expressed at the cytoplasmic level, especially in neural tissues, and is essential for neuronal triacylglycerol breakdown and membrane function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DDHD domain-containing protein 2 (DDHD2).